Published in Nat Immunol on August 01, 2010
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39
Oral tolerance. Immunol Rev (2005) 3.48
The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity (2011) 3.32
IL-12 family cytokines: immunological playmakers. Nat Immunol (2012) 3.12
Oral tolerance. Immunol Rev (2011) 3.03
Diesel exhaust particle induction of IL-17A contributes to severe asthma. J Allergy Clin Immunol (2013) 2.62
Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat Immunol (2012) 2.49
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol (2013) 2.33
An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2010) 2.21
Intestinal commensal microbes as immune modulators. Cell Host Microbe (2012) 2.07
Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant (2011) 1.96
Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med (2016) 1.96
CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nat Immunol (2011) 1.75
Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev (2010) 1.61
Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. Cell (2015) 1.60
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target. Toxicol Sci (2013) 1.53
IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol (2013) 1.50
Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer (2014) 1.46
Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol Rev (2013) 1.38
Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat Med (2015) 1.35
Mechanisms controlling Th17 cytokine expression and host defense. J Leukoc Biol (2011) 1.33
Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2012) 1.31
AhR sensing of bacterial pigments regulates antibacterial defence. Nature (2014) 1.30
Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia (2011) 1.29
Plasticity of human CD4 T cell subsets. Front Immunol (2014) 1.25
Type 1 regulatory T cells (Tr1) in autoimmunity. Semin Immunol (2011) 1.24
Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest (2013) 1.23
Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo. PLoS One (2013) 1.21
In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling. PLoS One (2011) 1.10
Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol (2012) 1.09
IL-21 induces IL-22 production in CD4+ T cells. Nat Commun (2014) 1.05
The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response. Immunology (2013) 1.04
Aryl hydrocarbon receptor and colitis. Semin Immunopathol (2013) 1.02
Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01
Control of immune-mediated pathology via the aryl hydrocarbon receptor. J Biol Chem (2017) 0.98
Dysregulation of immune homeostasis in autoimmune diseases. Nat Med (2012) 0.98
Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes Cells (2013) 0.97
Functions of the aryl hydrocarbon receptor in the skin. Semin Immunopathol (2013) 0.95
Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol (2014) 0.93
Interleukin-6 induces the generation of IL-10-producing Tr1 cells and suppresses autoimmune tissue inflammation. J Autoimmun (2012) 0.93
Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same? Clin Dev Immunol (2011) 0.92
Mechanisms of tolerance and allergic sensitization in the airways and the lungs. Curr Opin Immunol (2010) 0.90
Indoles mitigate the development of experimental autoimmune encephalomyelitis by induction of reciprocal differentiation of regulatory T cells and Th17 cells. Br J Pharmacol (2013) 0.89
SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation. PLoS One (2012) 0.89
Aryl Hydrocarbon Receptor-Mediated Perturbations in Gene Expression during Early Stages of CD4(+) T-cell Differentiation. Front Immunol (2012) 0.88
Intragraft CD11b(+) IDO(+) cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions. Am J Transplant (2012) 0.88
Ikaros sets the potential for Th17 lineage gene expression through effects on chromatin state in early T cell development. J Biol Chem (2013) 0.88
Aryl hydrocarbon receptor promotes RORγt⁺ group 3 ILCs and controls intestinal immunity and inflammation. Semin Immunopathol (2013) 0.87
Negative regulators take center stage. Nat Immunol (2012) 0.86
In vivo dioxin favors interleukin-22 production by human CD4+ T cells in an aryl hydrocarbon receptor (AhR)-dependent manner. PLoS One (2011) 0.86
The environment of regulatory T cell biology: cytokines, metabolites, and the microbiome. Front Immunol (2015) 0.86
Aryl hydrocarbon receptor: Linking environment to immunity. Semin Immunol (2015) 0.86
Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease. PLoS One (2014) 0.86
Toward understanding the role of aryl hydrocarbon receptor in the immune system: current progress and future trends. Biomed Res Int (2014) 0.84
Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology (2014) 0.84
Regulation of the T Cell Response by CD39. Trends Immunol (2016) 0.83
Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients. PLoS One (2014) 0.83
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A (2016) 0.83
Role and therapeutic value of dendritic cells in central nervous system autoimmunity. Cell Death Differ (2014) 0.83
New Trends in Aryl Hydrocarbon Receptor Biology. Front Cell Dev Biol (2016) 0.82
Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer. Front Immunol (2013) 0.82
The role of nuclear receptors in regulation of Th17/Treg biology and its implications for diseases. Cell Mol Immunol (2015) 0.82
Differential regulation of Th17 and T regulatory cell differentiation by aryl hydrocarbon receptor dependent xenobiotic response element dependent and independent pathways. Toxicol Sci (2015) 0.82
Polycyclic aromatic hydrocarbons reciprocally regulate IL-22 and IL-17 cytokines in peripheral blood mononuclear cells from both healthy and asthmatic subjects. PLoS One (2015) 0.82
AHR Function in Lymphocytes: Emerging Concepts. Trends Immunol (2015) 0.82
In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol (2014) 0.81
How T cells take developmental decisions by using the aryl hydrocarbon receptor to sense the environment. Proc Natl Acad Sci U S A (2010) 0.80
Metabolomics Reveals that Aryl Hydrocarbon Receptor Activation by Environmental Chemicals Induces Systemic Metabolic Dysfunction in Mice. Environ Sci Technol (2015) 0.80
ITE, a novel endogenous nontoxic aryl hydrocarbon receptor ligand, efficiently suppresses EAU and T-cell-mediated immunity. Invest Ophthalmol Vis Sci (2013) 0.80
Role of the aryl hydrocarbon receptor in the immune response profile and development of pathology during Plasmodium berghei Anka infection. Infect Immun (2014) 0.80
Host-microbiome interactions: the aryl hydrocarbon receptor and the central nervous system. J Mol Med (Berl) (2016) 0.80
Role of the aryl hydrocarbon receptor in the pathogenesis of chronic rhinosinusitis with nasal polyps. Inflammation (2014) 0.79
Transplantation tolerance: Clinical potential of regulatory T cells. Self Nonself (2011) 0.79
NK-DC crosstalk controls the autopathogenic Th17 response through an innate IFN-γ-IL-27 axis. J Exp Med (2015) 0.79
Breast Milk and Solid Food Shaping Intestinal Immunity. Front Immunol (2015) 0.79
Regulation of central nervous system autoimmunity by the aryl hydrocarbon receptor. Semin Immunopathol (2013) 0.79
AHR promoter variant modulates its transcription and downstream effectors by allele-specific AHR-SP1 interaction functioning as a genetic marker for vitiligo. Sci Rep (2015) 0.79
A toxin-sensitive receptor able to reduce immunopathology. Nat Immunol (2010) 0.79
Purinergic signaling during intestinal inflammation. J Mol Med (Berl) (2017) 0.79
Purinergic Signaling as a Regulator of Th17 Cell Plasticity. PLoS One (2016) 0.78
AHR Activation Is Protective against Colitis Driven by T Cells in Humanized Mice. Cell Rep (2016) 0.78
Tolerogenic dendritic cells. Semin Immunopathol (2016) 0.78
Mechanisms of immunological tolerance in central nervous system inflammatory demyelination. Clin Exp Neuroimmunol (2015) 0.77
Suppression of acute graft-versus-host response by TCDD is independent of the CTLA-4-IFN-γ-IDO pathway. Toxicol Sci (2013) 0.77
Constitutive aryl hydrocarbon receptor signaling constrains type I interferon-mediated antiviral innate defense. Nat Immunol (2016) 0.77
Extra-thymically induced T regulatory cell subsets: the optimal target for antigen-specific immunotherapy. Immunology (2015) 0.77
Aryl Hydrocarbon Receptor Protects Lungs from Cockroach Allergen-Induced Inflammation by Modulating Mesenchymal Stem Cells. J Immunol (2015) 0.77
Impact of dietary components on NK and Treg cell function for cancer prevention. Mol Carcinog (2015) 0.77
Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages. Vaccines (Basel) (2015) 0.76
T-cell activation or tolerization: the Yin and Yang of bacterial superantigens. Front Microbiol (2015) 0.76
Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and mice. Immunol Cell Biol (2014) 0.76
Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation. J Neuroinflammation (2015) 0.76
Sinomenine induces the generation of intestinal Treg cells and attenuates arthritis via activation of aryl hydrocarbon receptor. Lab Invest (2016) 0.75
LeA(H)Rning self-control. Cell Res (2014) 0.75
Collaborative control of induced regulators. Nat Rev Immunol (2010) 0.75
Tr1-Like T Cells - An Enigmatic Regulatory T Cell Lineage. Front Immunol (2016) 0.75
Aiolos and Lymphocyte Mimicry in Lung Cancer. Mol Cell Oncol (2014) 0.75
A human proteome array approach to identifying key host proteins targeted by Toxoplasma kinase ROP18. Mol Cell Proteomics (2017) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40
A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 16.28
Smad transcription factors. Genes Dev (2005) 13.43
How regulatory T cells work. Nat Rev Immunol (2008) 11.66
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature (2008) 10.15
Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature (2008) 9.32
The regulation of IL-10 production by immune cells. Nat Rev Immunol (2010) 9.18
Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol (2007) 6.92
Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature (2010) 6.87
IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol (2008) 6.41
Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol (2007) 6.22
Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev (2006) 6.08
Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol (2002) 5.91
Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity (1999) 5.50
Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol (2007) 5.45
Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 4.11
The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol (2010) 4.06
The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest (2005) 3.83
The transcription factor c-Maf controls the production of interleukin-4 but not other Th2 cytokines. Immunity (1999) 3.61
Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med (2008) 3.50
Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci U S A (2008) 3.34
TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol (2007) 3.02
Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome. Immunity (2009) 2.84
Haematopoietic cell-fate decisions, chromatin regulation and ikaros. Nat Rev Immunol (2002) 2.76
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. EMBO J (1997) 2.71
Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. Immunity (2007) 2.65
Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity (2009) 2.61
Human regulatory T cells and their role in autoimmune disease. Immunol Rev (2006) 2.56
Control of cytochrome P1-450 gene expression by dioxin. Science (1985) 2.37
c-Maf regulates IL-10 expression during Th17 polarization. J Immunol (2009) 1.99
Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun (2008) 1.89
Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood (2008) 1.58
Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy (2009) 1.53
DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity (2000) 1.52
Functional characterization and gene expression analysis of CD4+ CD25+ regulatory T cells generated in mice treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Immunol (2008) 1.38
Interaction of Maf transcription factors with Pax-6 results in synergistic activation of the glucagon promoter. J Biol Chem (2001) 1.30
Therapeutic potential of FOXP3(+) regulatory T cells and their interactions with dendritic cells. Hum Immunol (2009) 1.17
Suppression of experimental autoimmune uveoretinitis by inducing differentiation of regulatory T cells via activation of aryl hydrocarbon receptor. Invest Ophthalmol Vis Sci (2009) 1.14
Foxp3+CD4+ T cell-mediated immunosuppression involves extracellular nucleotide catabolism. Trends Immunol (2008) 1.07
Combinatorial effects of splice variants modulate function of Aiolos. J Cell Sci (2007) 1.04
Production of Ah receptor ligands in rat fecal suspensions containing tryptophan or indole-3-carbinol. Nutr Cancer (1991) 0.94
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature (2008) 9.32
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med (2004) 8.98
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet (2009) 7.16
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med (2003) 6.73
A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol (2007) 6.20
Induction and molecular signature of pathogenic TH17 cells. Nat Immunol (2012) 4.43
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-α-PU.1 pathway. Nat Med (2010) 4.24
The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol (2010) 4.06
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Oral tolerance. Immunol Rev (2005) 3.48
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med (2006) 2.93
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest (2012) 2.67
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol (2009) 2.56
Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat Immunol (2012) 2.49
Perinatal outcomes associated with obstructive sleep apnea in obese pregnant women. Obstet Gynecol (2012) 2.48
T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc Natl Acad Sci U S A (2010) 2.41
The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A (2009) 2.38
Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary. Nat Rev Drug Discov (2008) 2.30
An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2010) 2.21
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol (2004) 2.11
Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A (2010) 2.10
IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol (2009) 2.00
Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J Clin Invest (2007) 2.00
Wernicke's syndrome during parenteral feeding: not an unusual complication. Nutrition (2008) 1.97
Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol (2011) 1.93
Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation (2002) 1.80
PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol (2004) 1.78
CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol (2003) 1.75
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol (2011) 1.73
IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol (2006) 1.72
Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol (2004) 1.71
Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging (2009) 1.70
Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol (2010) 1.66
What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol (2007) 1.64
Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol (2006) 1.63
A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev (2006) 1.62
Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest (2008) 1.61
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J Immunol (2006) 1.58
Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging (2002) 1.57
T-cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif. FASEB J (2006) 1.57
Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis. Ann Neurol (2010) 1.56
Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci (2005) 1.54
Neuroprotective features of mesenchymal stem cells. Best Pract Res Clin Haematol (2011) 1.53
Immunotherapeutic approaches to Alzheimer's disease. Science (2003) 1.52
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler (2013) 1.51
IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol (2013) 1.50
AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther (2009) 1.48
Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol (2008) 1.48
Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology (2013) 1.46
Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One (2013) 1.45
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest (2005) 1.45
Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol (2010) 1.42
Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J Immunol (2003) 1.40
Mesenteric lymph nodes are critical for the induction of high-dose oral tolerance in the absence of Peyer's patches. Eur J Immunol (2002) 1.40
Do tubers contain function? Resection of epileptogenic foci in perirolandic cortex in children with tuberous sclerosis complex. Epilepsia (2010) 1.39
Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J Immunol (2007) 1.39
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36
Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-mutant mice. Proc Natl Acad Sci U S A (2012) 1.35
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain (2008) 1.34
Gut-tropic T cells that express integrin α4β7 and CCR9 are required for induction of oral immune tolerance in mice. Gastroenterology (2011) 1.34
Systems biology approaches for the study of multiple sclerosis. J Cell Mol Med (2008) 1.33
Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9 expression. Mol Ther (2006) 1.33
MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS. Glia (2012) 1.32
Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset. J Immunol (2010) 1.31
Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2012) 1.31
Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.30
Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes (2007) 1.29
MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology (2003) 1.29
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med (2012) 1.29
Tumor suppressor RARRES1 interacts with cytoplasmic carboxypeptidase AGBL2 to regulate the α-tubulin tyrosination cycle. Cancer Res (2011) 1.28
Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol (2004) 1.28
Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol (2008) 1.26
Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci U S A (2010) 1.26
Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol (2006) 1.26
The importance of cell-mediated immunity in the course and severity of autoimmune anti-glomerular basement membrane disease in mice. FASEB J (2003) 1.25